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Abstract
Objectives To study and identify the determinants of the impact on pain, function, and quality of life of a prosthetic replacement
surgery after 5 years of survival in patients with osteoarthritis (OA) of the lower limb.
Method In total, 626 osteoarthritic patients from a University Hospital, divided in 2 groups (according to surgical
site), were prospectively followed for 5 years after hip (n = 346) or knee (n = 280) replacement. Validated specific
Western Ontario and McMaster Universities Arthritis Index (WOMAC) and generic (SF-36 and EQ) instruments
assessing quality of life were used prior to surgery and yearly, thereafter. We defined a good outcome as a clinically
relevant improvement in WOMAC greater than or equal to the minimally important difference (MID). Regressions
showed the relationships among preoperative, perioperative, and postoperative measures and the evolution of
WOMAC scores after 5 years (percent change). We also examined any predictors of good outcomes.
Results The beneficial effect on quality of life observed during the first year after hip and knee arthroplasty (HA and KA) was
maintained for up to 5 years. More than 3/4 of the patients in our study experienced a good outcome (86.04% in HA group and
79.91% inKA group). Both the good outcome and the 5-year change inWOMAC are predicted by preoperative (i.e., radiological
severity, comorbidities, disability, and level of education), perioperative (i.e., length of hospital stay and place of discharge), and
postoperative (i.e., complications) variables in the two groups.
Conclusions Joint arthroplasty is a highly valuable therapeutic strategy for hip or knee OA patients who do not respond to
pharmacological management. These results represent a step towards the collection of robust, scientifically sound data that will
facilitate the completion of health economic analyses in the field of OA.
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Key Points:
• This study reports the long term outcomes of hip and knee replacement surgery in late-stage OA.
•We identified pre-, per-, and post-operative determinants which contribute to a greater improvement in pain and function, hence increasing patients’
satisfaction.
• These results could contribute to select an OA population which has a high probability to get an optimal benefit from total joint replacement.
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Introduction
Osteoarthritis (OA) affects 240 million people globally, ap-
proximately 10% of men and 18% of women, especially el-
derly patients. OA is the third most common diagnosis made
by general practitioners in older patients [1, 2]. Due to an
aging society and obesity, the prevalence rates of knee
(KOA) and hip (HOA) OA are continuously rising. OA of
the lower limb represents an important clinical, social, ethical,
and economic burden from a societal perspective [3].
Different therapeutic options have been proposed by scientific
societies [4–6]. Surgical management, including joint replace-
ment, is recommended for patients who do not appropriately
respond to pharmacological management or those who have
late-stage OA. In most developed countries, the number of hip
or knee arthroplasties (HA and KA) has increased substantial-
ly over the past few years, along with increased costs [7]. The
outcomes of surgical management are generally recognized as
very satisfactory, with an increase in the life span. In addition,
HA is a safe and reliable procedure for the treatment of end-
stage arthritis in the young with good to excellent mid-term
results [8]. However, arthroplasty can result in adverse health
consequences; the most problematic is revision surgery [9].
Therefore, it is important to carefully evaluate the patient’s
benefits of these surgical interventions. In a previous study,
we demonstrated fast (from 3 months), substantial, and short-
term benefits of HA and KA on parameters reflecting quality
of life and health utility [10]. We have continued a 5-year
follow-up of this large number of OA patients, from both
genders, who underwent joint replacement of the knee or
hip. The objective of the present study was to determine
whether the benefits observed during the first year were main-
tained or improved over time and to clarify their determinants.
Our purpose was not to compare HA and KA.
Materials and methods
After prior approval from the Institutional Review Board
(IRB), 845 consecutive patients hospitalized at the
University Hospital of Liege in Belgium were considered el-
igible for the study. The sample size was evaluated based on
previous publications looking at similar parameters. The
patients, aged 18 years older, presented with end-stage HOA
or KOA (diagnosis based on the clinical and radiographic
criteria of the American College of Rheumatology and
established in case of inappropriate response to pharmacolog-
ical management, according to scientific guidelines [4–6])
needed joint replacement. A total of 626 subjects fulfilled
the inclusion criteria and received the first questionnaire.
They were divided in 2 groups (according to surgical site)
and were monitored over time from the day before surgery
to 5 years after surgery. The full details of the methodology
for recruitment and follow-up were previously described [10,
11]. During the 5-year follow-up, the evaluation of postoper-
ative outcomes continued through mail on a yearly basis.
The data collected referred to and related to patient’s char-
acteristics, comorbidities, radiological severity, quality of life,
and the clinical impacts of OA.We recorded age, gender, body
mass index (BMI), duration of knee or hip complaints, and
previous traumatic or surgical history of the lower limbs (in-
formation was also obtained by consulting the medical files).
The Functional Comorbidity Index (FCI) was used to re-
cord comorbidities throughout the 5 years. This specific, val-
idated instrument was developed to assess the status of pa-
tients undergoing joint replacement. The score ranges from 0
to 18, depending on the presence of 18 diagnoses associated
with declining function [12]. X-rays of the target joint were
scored according to the Kellgren–Lawrence (KL) grading sys-
tem [13].
The occurrence of complications was registered and mon-
itored during the 5-year follow-up. These were structured and
clustered into 3 categories: early postoperative complications
(within 30 days of surgery), 1-year postoperative complica-
tions, and late-onset complications (up to 5 years).
We chose generic instruments for the assessment of quality
of life ((36-item short-form health survey (SF-36)) and utility
(EuroQol (EQ) health-related quality of life instrument). The
Western Ontario and Mac Master Universities Arthritis
Questionnaire (WOMAC) was selected as a specific OA in-
strument. The WOMAC covered 3 specific fields: pain, stiff-
ness, and physical function [14]. Lower values reflect a better
health status (scores range between 0 and 96). The SF-36 is a
popular tool for assessing health-related quality of life
(HRQOL) in many physical health conditions [15]. The 8
individual subscales are divided across the physical domains
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of physical function (PF), role physical (RP), bodily pain
(BP), and global health (GH) and the psychological domains
of vitality (V), social function (SF), role emotional (RE), and
mental health (MH). Higher scores represent better health
(scores range from 0 to 100). The EQ measures utility in 2
ways: a health state classification (in five domains: 5D) rang-
ing from 0 to 1, in which 1 represents full health and 0 is
death), and an evaluation using a visual analog scale (VAS;
ranging from 0 to 100 according to the same logic) [16].
We determined the percentage variation in the total
WOMAC score after 5 years. The concept of a “good out-
come”, which is established if the enhancement in total
WOMAC is greater than or equal to the minimally important
difference (MID), makes it possible to see if the WOMAC
improvement is clinically relevant. MID represents one-half
of the SD of the difference between the pre-surgery summary
score and the 5-year post-surgery summary score. MID allows
us to interpret the clinical significance of the mean differences
or to determine the proportion of patients who experience
clinically important changes [17].
Statistical analysis
We recorded basic demographic variables including age, gen-
der, study level, income level, BMI, FCI, KL grade, and sur-
gical or traumatic history. We examined intraoperative vari-
ables including the type of prosthesis, type of fixation, type of
weight-bearing surfaces, and postoperative variables includ-
ing hospital length of stay (LOS), location of discharge
(discharged to home or to another facility), and complications.
After the verification of data normality and homogeneity, we
processed nonparametric statistical analysis. Continuous var-
iables are expressed as the means with standard deviations
(SDs) for the visual relevance. The proportions that met our
criteria for a good outcome were calculated with 95% confi-
dence intervals (95% CIs) for hip and knee replacement recip-
ients separately. The comparisons between baseline measures
(EQ and WOMAC) and follow-up measures (1 year to 5
years) were conducted using Wilcoxon signed-rank tests (2
samples). Second, data from the 1-year follow-up and the 2-
to 5-year follow-up were compared using Friedman’s analysis
of variance and the Wilcoxon signed-rank test. Univariate and
multivariable regression analyses were performed to deter-
mine whether preoperative patient’s characteristics, intraoper-
ative, or postoperative variables influenced our main outcome
at 5 years (variation in the total WOMAC score). A signifi-
cance level of 0.25 was used to include variables in the regres-
sion model before a backward selection procedure. Then, we
performed secondary analyses seeking associations between
these factors and good outcome using binary logistic back-
ward regression modeling. Finally, as previously performed,
we explored the profile of patients with long-term complica-
tions using the same statistical strategy [10]. The odds ratios
(ORs) associated with each of the identified predictors were
determined using logit regression. The data were analyzed
using Statistica version 13, on a Windows platform. The level
of statistical significance was set at p < 0.05, except for the
Wilcoxon signed-rank tests. For those, we adjusted the statis-
tical significance level based on the number of time point
comparisons (Bonferroni correction: p < 0.05/4 = 0.0125
and p < 0.05/5 = 0.01).
Results
Population characteristics
Of 845 individuals with lower limb OAwho were invited to
participate, 219 were not included due to language problems
or insufficient literacy (n = 26; 3.08%), lack of consent (n =
161; 19.05%), or reduced preoperative cognitive, sensory, or
physical capacity (n = 32; 3.79%). Of the remaining 626 in-
dividuals, 280 received KA (44.73%) and 346 underwent HA
(55.27%). The participants’ median (P25–P75) age was 66
(59–73) years; 56.8% of the patients were female. Table 1
shows the characteristics of the study population at baseline
and the specified intraoperative and postoperative parameters,
which are already largely detailed in the two previous publi-
cations on this patient cohort.
HA, hip arthroplasty; KA, knee arthroplasty; BMI, body
mass index; KL, Kellgren–Lawrence; CPRS, complex region-
al pain syndrome
Persistence
We are able to follow 76% of our population to the end of 5
years (Fig. 1). The reasons for the lack of participation are
related to willingness, time consumption, or personal prob-
lems. Only 15 patients in the KA group (5%) and 5 patients
in the HA group (1%) decided to discontinue the study due to
problems directly related to the surgical procedure. The 147
patients who prematurely discontinued the study were older
(68.02 vs 64.84 years, p < 0.05), had more comorbidities (2.79
vs 2.42, p < 0.05), and had a lower quality of life (regarding
the EQ instrument: 60.92 vs 64.46 for EQ-VAS and 0.38 vs
0.46 for EQ-5D). However, we did not observe any difference
in radiological severity (KL, p = 0.33) or in pain, function, or
stiffness (WOMAC, p = 0.12).
EQ evolution
The EQ-5D/VAS health utility scores were significantly im-
proved at the 12th postoperative month in both groups (p <
0.01). The values remained stable for up to 5 years in the KA
group (p = 0.11 for EQ-VAS and p = 0.28 for EQ-5D). In the
HA group, the improvement was actually maximal at the 1-
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year postsurgical follow-up. After that, the EQ-5D and VAS
scores decreased slightly and were significantly better
compared with that in the 1-year follow-up (p = 0.04 for
EQ-5D and < 0.05 for EQ-VAS). The beneficial effect
Table 1 Characteristics




Variables KA (n = 280, 44.73%) HA (n = 346, 55.27%)
n % n %
or Mean ± SD or Mean ± SD
Patient’s characteristics
Age at the time of operation (years) 66.74 ± 8.95 64.64 ± 10.85
Gender: female 152 54.29 204 58.96
Educational level
No education 3 1.07 0 0
Primary school 44 15.71 34 9.83
Lower secondary school 68 24.29 76 21.97
Upper secondary school 85 30.36 118 34.10
Higher education 80 28.57 118 34.10
BMI 29.31 ± 4.71 27.42 ± 4.79
Surgical/traumatic background 97 36.64 22 6.36
FCI 2.41 ± 1.25 2.63 ± 1.25
KL score (distribution) n = 273 n = 339
1 12 4.4 23 6.78
2 43 15.75 83 24.48
3 188 68.86 123 36.28
4 30 10.99 110 32.45
Procedure characteristics
Type of prosthesis
Unicompartimental (KA group) or Resurfacing (HA group) 14 5 9 2.60







Length of hospital stay (days) 8.62 ± 3.03 7.51 ± 7.02
Discharge status: nursing home or rehabilitation facility 93 33.45 80 23.12
Early postoperative complication 38 13.57 38 10.98
1st year postoperative complication 61 21.79 25 7.23
Late-onset complication 23 8.21 37 10.72
Aseptic loosening 3 1.07
CRPS 1 0.36
Periprosthetic fracture 1 0.36 2 0.58
Infection 2 0.71
Patellar complaint or knee resurfacing 9 3.21
Muscle or ligament problem 6 2.14 30 8.69
Dislocation 3 0.87
Heterotopic ossification 1 0.36 1 0.29
Death 1 0.29
Major complication 28 8.12 30 10.71
HA, hip arthroplasty; KA, knee arthroplasty; BMI, body mass index; KL, Kellgren–Lawrence; CPRS, complex regional
pain syndrome. Number of patients for whom preoperative radiography was available set in italic
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observed after 1 year in terms of quality of life were main-
tained for up to 5 years of follow-up and was still significantly
higher than the clinical preoperative status in the two groups
(p < 0.01). At this time point, utility (EQ-5D) was improved to
48% (HA) and 39% (KA) compared with what was recorded
at baseline (Fig. 2).
WOMAC evolution
Compared with the baseline scores, the total WOMAC score
and all of the subscale scores were significantly improved 12
months after surgery (p < 0.01) and further improved over
time (p < 0.01) compared with the baseline scores. After 3
years (KA) and 5 years (HA), some parameters were slightly
better than the improvement recorded after 1 year (p < 0.01)
(Fig. 3).
SF-36 evolution
Regarding the SF-36, in the HA group, maximal improve-
ments were observed 1 year after surgery in 3 physical do-
mains (PF/BP/GH), in the mental domain (MH) and in the
overall health change. This period of maximal improvement
was followed by a gradual diminution with better data at 5
years than at the preoperative level. The maximum values in
the last physical domain (RP) and 2 other mental domains (SF/
RE) were achieved at 3 years. In the KA group, the peak
values were observed later (1 year for MH and VT; 3 years
for BP; and 4 years for PF, RP, SF, and, RE). In the two study
groups, the general health perceptions were maximal at 1 year
and returned to the preoperative levels at 5 years.
WOMAC determinants
In the final multivariate linear regression (Table 2), severe
radiological OA at baseline and the absence of late postoper-
ative complications were positive predictive factors of a ben-
eficial outcome after 60 months in patients with HA.
WOMAC, Western Ontario and McMaster Universities
Osteoarthritis Index; HA, hip arthroplasty; KA, knee
arthroplasty; FCI, functional comorbidity index; 1-y, 1-year
In patients with KA, a low number of comorbidities, an
early discharge from the hospital, a discharge to home, and
the absence of complications (1-year and late) were identified
as positive predictive factors. Patients with a greater preoper-
ative stiffness on WOMAC were more likely to experience
greater improvement. The level of education favorably influ-
ences the evolution of outcome scores.
These parameters explain the 17% and 24% of the variance
of the WOMAC total score in the HA group and KA group,
respectively.
Good outcome determinants
The mean improvements in hip/knee WOMAC summary
scores were 37.68 ± 22.75 and 25.78 ± 21.84, respectively.
The calculated MID for WOMAC summary scores is an 11-
point improvement for the hip and a 10-point improvement for
the knee. More than 3/4 of patients meet the MID criterion for
good outcome (86.04%, 95% CI: 81.86–90.21 in the HA
group; and 79.91%, 95% CI: 74.54–85.28 in the KA group).
The determinants of “good outcome” in the HA group were
a higher preoperative disability score (OR 1.04, 95% CI 1–
1.07, p = 0.03), lack of comorbidities (OR 0.71, 95%CI 0.51–
Fig. 1 Flowchart representing follow-up of patients
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0.97, p = 0.03), and the absence of postoperative complica-
tions (OR 0.17, 95% CI 0.07–0.41, p < 0.001).
In patients with KA, the degree of preoperative stiffness
(OR 1.42, 95% CI 1.13–1.77, p = 0.002), level of education,
degree of radiological severity (OR 2.43 95% CI 1.34–4.38, p
= 0.003), lack of comorbidities (OR 0.67, 95% CI 0.51–0.87,
p = 0.003), place of discharge (OR 3.89, 95% CI 1.70–8.92, p
= 0.001), and length of hospital stay (OR 0.88, 95% CI 0.77–
0.99, p = 0.046) were identified as predictors for good
outcome.
Late-onset complications
We previously published the rate of early complications in
both procedures [10]. At the 5-year postsurgical follow-up
(Table 1), the complication rate was 10.72% for patients
who experienced HA and 8.21% for those who underwent
KA. In the HA group, the most frequent complication was
dislocation (1.16%). A total of 8.99% of patients in the HA
group had persistent pain due to muscle/ligament disorder.
The most frequent complication in the KA group was patellar
pain (3.23%). Muscle/ligament disorder was present in 2.15%
of the patients. Throughout the study, 6 patients were affected
by infectious complications: 4 during the 1st year and 2 during
the long-term follow-up (2 in the HA group and 4 in the KA
group), i.e., less than 1% of our cohort.
Discussion
In our large study, we noted that the positive impact of HA and
KA on HRQOL observed after 3 months continues and re-
mains statistically significant over time (up to 5 years) com-
pared with the clinical condition before surgery [10]. In par-
ticular, quality of life and specific OA symptoms (pain, stiff-
ness, and function) were better than they were before
arthroplasty. Earlier analyses were not performed given that
no substantially different outcomes between the 12- and 48-
month follow-up were observed. These findings are entirely
consistent with a recent review [18].
Most studies published in recent years have established a
positive impact of HA and KA on HRQOL [19, 20]. Disease-
specific measures are more accurate for assessing immediate
effects, whereas generic measures reveal the long-term effects
of an intervention in overall function. All health domains on
the SF-36 were superior or similar to those at baseline over a
follow-up of 5 years. As one might expect, the physical do-
mains (PF, RP, BP, and GH) reveal the largest benefits. In
addition, benefit has also been observed in the psychosocial
domains (VT, RE, MH, and SF) after HA and KA, even
though this may not be the primary goal of surgery. The sta-
bilization phase observed from 12 months to 5 years after
surgery can be attributed to aging (e.g., an increasing number
of comorbidities and multiple sites of OA). However,
HRQOL remains above the preoperative level. Logically,
Fig. 2 EQ-5D and EQ-VAS evolution over time (mean and SD). EQ-
VAS EuroQol visual analog scale; scored from 0 to 100, EQ-5D EuroQol
5 dimensions of health; scored from 0 to 1, PO postoperative. *Significant
difference (p < 0.01) compared with baseline (Wilcoxon test).
ΔSignificant difference (p < 0.01) compared with the 1-year follow-up
(Wilcoxon test)
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physical components experience the greatest improvements,
which is consistent with previous studies [19, 20].
The improvement also applies to EQ and goes in the same
direction. These data may contribute to the conduct of health
economics studies with the objective of evaluating whether
arthroplasty of the lower limb in patients with OA can be
considered a cost-effective procedure with a quality-adjusted
life-year (QALY) gain [21]. This surgery could then be com-
pared to other surgical procedures that are frequently conduct-
ed in a population of the same age with the objective to better
allocate health resources. Similar analyses were conducted in
themusculoskeletal field, aswas the case for lumbar surgery in
patients presenting with spinal stenosis [22].
RegardingWOMACand its subscales,weobserved a short-
term benefit that even improved until 60 months of follow-up.
Most studies also described improvements in WOMAC after
HA for 12 to 18 months postoperation with a subsequent pla-
teau effect [19]. Regarding KA, the majority of benefits were
demonstrated within 1 year of surgery. Following this,
HRQOL was reported to slightly improve, to be maintained,
or to decline but remains superior to preoperative levels [20].
Interpreting HRQOL scores is a challenging task. Multiple
definitions have been proposed to evaluate lower limb
arthroplasty benefits, including improvements in symptoms,
quality of life, and patient satisfaction [17, 23]. Because joint
pain is the most common reason people seek arthroplasty, it
seems reasonable that evaluation of the surgical benefits incor-
porates improvement in pain [24]. The MID, defined in 2005
from the MCID, facilitated understanding of the importance of
intervention effects, particularly patient-reported outcomes
scores such as WOMAC scores[17]. In our study, we sought
to determine the principal drivers of long-term outcomes,
Table 2 Prediction of a higher
variation in WOMAC total score
5 years after HA and KA in the
multivariate analysis (final
model).
Predictors Postoperative WOMAC total score
B (95% confidence interval) p value
KA model (R2 = 0.24)
Level of education 7.33 (1.99 to 12.38) < 0.01
FCI − 6.01 (− 9.66 to − 2.37) < 0.01
Length of stay − 2.18 (− 4.21 to − 0.15 ) 0.04
Place of discharge following hospital stay − 20.31 (− 32.02 to − 8.60) < 0.001
1-y postoperative complications − 18.92 (− 31.70 to − 6.14) < 0.01
Late postoperative complications − 27.43 (− 46.44 to − 8.42) < 0.01
Preoperative stiffness 4.13 (1.11 to 6.98) < 0.01
Constant 60.74 (33.11 to 88.36) < 0.001
HA model (R2 = 0.17)
Radiological severity 5.11 (0.60 to 9.62) 0.03
Late postoperative complications − 42.01 (− 54.37 to − 29.65) < 0.001
Constant 59.73 (45.81 to 73.64) < 0.001
WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; HA, hip arthroplasty; KA, knee
arthroplasty; FCI, functional comorbidity index; 1-y, 1-year
Fig. 3 WOMAC and component evolution over time (mean and standard
deviation). WOMAC Western Ontario and McMaster Universities
Osteoarthritis Index; scored from 0 to 96. *Significant difference (p <
0.01) compared with baseline (Wilcoxon test). ΔSignificant difference
(p < 0.01) compared with the 1-year follow-up (Wilcoxon test)
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particularly the 5-yearWOMACscore and the achievement of a
“good” outcome, which is defined as a clinically important
improvement in WOMAC. More than 3/4 of the patients in
our study met the MID criterion for a good outcome. This rate
is consistent with that of the previously published patient-
reported outcomes after lower limb arthroplasty [25].
Various preoperative, intraoperative, and postoperative
variables can predict patients who experience good 5-
year outcomes. Regarding the predictors for 5-year out-
comes, we found common parameters in HA and KA
patients, such as radiological severity, postoperative
complications, preoperative clinical parameters, and
comorbidities.
Among the preoperative parameters, worse preoperative
function and radiological severity of OAwere associated with
larger postoperative improvement in the HA group. This find-
ing is consistent with what has been published in a recent
review [26], although some authors do not agree with this
analysis [27]. Postoperative complications also impacted the
outcome at 5 years.
Regarding intraoperative and postoperative variables in the
KA group, a long hospital stay, a high preoperative stiffness,
and a discharge to another facility other than home and the
first-year complications are significant predictors of a poor
outcome after 5 years. We observed that the radiological se-
verity of KOA is a positive predictor for “good outcome”.
Previously, preoperative arthritis severity was observed as a
predictor of KA satisfaction [28]. The study level also affected
outcome evolution in the KA group.
The number of comorbidities appears to have a long-term
effect on patient outcome after arthroplasty. This result is con-
sistent with another study, showing that comorbidities were
one of the predictors that are significantly associated with
smaller QALY gains after KA [29]. The association between
a higher number of comorbidities and worse outcomes seems
to be stronger in HA than in KA [30]. Presurgical comorbid-
ities must not be an overall hindrance to arthroplasty because
the mortality rates have decreased substantially over the past
two decades [31]. Nonetheless, it should not be forgotten that
patients with quite a few comorbidities reported more compli-
cations [32], which is also the case in our study. The type of
prosthesis did not influence the outcome.
We did not demonstrate any influence of age, gender, or
BMI on the postoperative outcome, as other studies have [26].
Obesity is associated with an increased risk of late-life mobil-
ity limitation after arthroplasty [33]. We did not find any im-
pact of it in our study.
Dowsey elegantly addressed a similar issue from an alter-
native perspective in 2016 [34]. He developed and validated a
prognostic tool to predict a nonresponse, 1 year after knee
surgery. This approach could be considered in our population
to identify the determinants of a bad result (opposite to the
“good result”). In the future, this strategy could be applied to
both hip and knee arthroplasties in a long-term perspective to
identify modifiable risk factors predicting a poor outcome.
This may subsequently impact on clinical practice. The goal
would be to define threshold values, for some amendable var-
iables, above or below which a greater probability of a lesser
response to surgery occurs, hence allowing to correct these
parameters before joint replacement.
The main strength of our research is the population profile.
This study population is homogenous, and the surgical proce-
dures were performed in the same surgical center, applying a
standardized surgical and rehabilitation protocol. The pro-
spective longitudinal design (5 years) with preoperative data,
follow-up time points that were pre-determined at baseline
(with repeated attempts at contact to minimize loss to fol-
low-up), and the large sample size are also major assets.
This large cohort allows comparisons with other studies, most
of which include fewer patients. The preliminary results are
encouraging. Another major strength is the rate of retention
that was achieved. We were able to retain a large subset of our
population (76%) until the end of the follow-up (5 years). This
retention compares favorably with that observed in other stud-
ies [19, 20, 26]. We use previously validated HRQOL instru-
ments, including a generic instrument (SF-36), to facilitate the
holistic assessment of the health dimensions according to the
WHO’s HRQOL definition [35].
In contrast, strengths can be turned into weaknesses. A bias
may result from a single center study [36]. Regarding the
sample size, a number of patients less than 500 are a potential
source of bias in hip replacement studies and likewise for a
number less than 270 in knee replacement studies. We did not
achieve this number in the HA group, but it remains above the
number of patients in the majority of previously published
quality studies [19, 20]. In the same vein, a loss of < 15% of
patients to follow-up is considered ideal for treatment analyses
according to guidelines [37]. However, this theoretical thresh-
old ignores the length of follow-up. Accordingly, losing less
than 20% of patients to follow-up at 1 year is considered to
represent a low risk of bias. For a longer follow-up, an addi-
tional 10% loss to follow-up for each additional year is toler-
ated [26]. We are largely below this threshold for our 5-year
study: 24% of KA patients and 23% of HA patients were lost
to follow-up, and 5% and 1%, respectively, had arthroplasty
complications. The patients who discontinued the study were
an average older, had more comorbidities, and had a reduced
quality of life. However, their radiological and clinical (pain,
stiffness, and function) profiles were similar to those who
continued the study. Of course, we agree that patients who
are lost to follow-up are more likely to be ill, less satisfied,
or have poor outcomes. Inevitably, this can result in the dis-
creet selection bias common to prospective cohort studies.
Therefore, satisfied patients with good outcomes may be
over-represented [38]. Perhaps, it would have been better to
opt for telephone interviews to minimize the loss to follow-up.
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However, the mailed questionnaire reduced the recruitment
effort compared with the telephone interview [39].
Additionally, this study does not include a control group. It
would be interesting to compare the evolution of quality of life
on a reference population. In this specific case, a control pop-
ulation seems a priori impossible for a variety of reasons.
Sham operations are unthinkable for ethical reasons. On the
other hand, surgery is proposed when patients are not
responding to medications. It is inconceivable to leave pa-
tients at an advanced stage of disease and not to intervene.
Last but not the least, the population of inoperable patients
with end-stage OAwould be significantly different. The com-
parisons can be quite hazardous given the differences in co-
morbidities and potential contraindications. Finally, assessing
outcomes through self-reported questionnaires may bias the
results due to response shift [40].
Conclusions
In our large prospective population cohort that received hip or
knee replacement, 75% of the patients experienced a good
outcome 5 years after surgery. Thus, lower limb replacement
surgery benefits a large part of the community and is a thera-
peutic alternative not to be neglected in the management of
OA. This procedure may be recommended for patients who do
not respond to pharmacological treatment and for those who
have a late-stage OA or contraindications to medications.
These results provide information that can help determine
the optimal timing of surgery through the preoperative patient
status.
The findings represent a step towards the collection of ro-
bust, scientifically sound data that will pave the way for the
completion of health economic analyses in the field of OA. In
a cost-conscious approach, health-care resources must be
more substantial and better targeted to allow health interven-
tions to return the maximum benefit. In this context, the need
to identify patients with a high propensity to be good re-
sponders makes sense from an economic perspective. Thus,
this study offers a wide range of future perspectives.
Additionally, pharmacoeconomic modulation requires ro-
bust data to determine the effect on quality of life. The data
generated during 5 years of follow-up appeared to provide
such material. This study demonstrates the efficiency of re-
placement surgery compared with alternative strategies (mus-
culoskeletal area or many other areas of medicine).
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